Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Stock Short Interest Climbs 3,691.1%

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,297,436 shares, an increase of 3,691.1% from the August 31st total of 34,223 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 588,083 shares, the days-to-cover ratio is currently 2.2 days.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR presently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

OTCMKTS SGIOY opened at $9.20 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $15.66 billion, a P/E ratio of 9.20, a P/E/G ratio of 3.37 and a beta of 0.08. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $7.65 and a 12-month high of $12.00. The firm has a 50-day moving average price of $9.08 and a two-hundred day moving average price of $9.46.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its earnings results on Monday, August 3rd. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. The company had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $970.69 million. Analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.